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Blood formation by hematopoietic stem cells (HSCs) is regulated by a still incompletely defined network of general and HSC-specific
regulators. In this study, we analyzed the role of G-protein coupled receptor 56 (Gpr56) as a candidate HSC regulator based on its
differential expression in quiescent relative to proliferating HSCs and its common targeting by core HSC regulators. Detailed
expression analysis revealed that Gpr56 is abundantly expressed by HSPCs during definitive hematopoiesis in the embryo and in the
adult bone marrow, but its levels are reduced substantially as HSPCs differentiate. However, despite enriched expression in HSPCs,
Gpr56-deficiency did not impair HSPC maintenance or function during steady-state or myeloablative stress-induced hematopoiesis.
Gpr56-deficient HSCs also responded normally to physiological and pharmacological mobilization signals, despite the reported role of
this GPCR as a regulator of cell adhesion and migration in neuronal cells. Moreover, Gpr56-deficient bone marrow engrafted with
equivalent efficiency as wild-type HSCs in primary recipients; however, their reconstituting ability was reduced when subjected toAbbreviations: BMT, bone marrow transplantation; BFFP, bilateral frontoparietal polymicrogyria; G-CSF, granulocyte colony stimulating
factor; GPR56, G-protein coupled receptor 56; GPCRs, G-protein coupled receptors; HSCs, Hematopoietic stem cells; HSPCs, Hematopoietic
stem and progenitor cells; 5-FU, 5-Fluoro uracil.
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308 T.N. Rao et al.serial transplantation. These data indicate that although GPR56 is abundantly and selectively expressed by primitive HSPCs, its high
level expression is largely dispensable for steady-state and regenerative hematopoiesis.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY
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Hematopoietic stem cells (HSCs) are the only adult stem cells
that can sustain lifelong blood cell production through their
self-renewal and differentiation capacity. During embryonic
and adult hematopoiesis, HSC homeostasis is dynamically
regulated by facultative actions of cell-intrinsic and extrinsic
regulators (Orkin and Zon, 2008; Wilson et al., 2010). Recent
studies have identified several transcription factors as master
regulators of HSC homeostasis, including Runx1, Evi1, Gata2,
Scl, Erg, Lyl1, Lmo2, among others (Wilson et al., 2010; Ling et
al., 2004; Beck et al., 2013). In addition, HSC functional
properties and transcriptional programs are modulated by
extrinsic factors (including, cytokines, chemokines, growth
factors, and extracellular matrix proteins), which act through
HSC-expressed cell surface receptors (Wang andWagers, 2011;
Ehninger and Trumpp, 2011; Levesque and Winkler, 2011). In
adult bone marrow, HSCs reside in a specialized microenviron-
ment, called the stem cell ‘niche’. HSCs continuously
communicate with their niche, and depend on niche-derived
signals to maintain their survival, self-renewal, retention, and
differentiation capacity.
Over the last decade, several studies employing genome
wide transcriptional profiling analysis have revealed a unique
HSC transcriptional signature and suggested that genes
specifically and highly expressed in HSCs may determine HSC
functional properties (Wilson et al., 2010; Ramalho-Santos et
al., 2002; Gazit et al., 2013; Forsberg et al., 2010; Venezia et
al., 2004; Ivanova et al., 2002) and can even specify HSC fate
from more mature hematopoietic cells (Riddell et al., 2014).
Although such studies have focused largely on transcriptional
regulators of HSCs, it is clear that cell surface receptors can
play an equally important role in the maintenance and
regenerative function of stem cells by translating signals
from extracellular ligands into cell physiological changes
(Laird et al., 2008). G-protein coupled receptors (GPCRs)
constitute one of the largest and most diverse families of
membrane proteins and mediate many biological functions
through ‘outside in’ signaling between the cell and its
microenvironments (Venkatakrishnan et al., 2013). Yet,
despite their functional significance in numerous cell types,
few GPCRs have been investigated for their role in the
regulation of HSCs. For this reason, we sought to identify the
candidate HSC specific cell surface receptors by analysis of
published gene expression data sets (Wilson et al., 2010;
Venezia et al., 2004). From these studies, G-protein coupled
receptor 56 (Gpr56) emerged as a highly expressed HSC-
specific cell surface receptor that was present at increased
levels in quiescent relative to proliferating HSCs and targeted
by core HSC regulators.
GPR56 is a member of the adhesion type GPCR family
(Langenhan et al., 2013), and has been implicated in regulating
cell proliferation, survival, adhesion, and migration of variouscell types (Iguchi et al., 2008; Luo et al., 2011a), although its
physiological role in hematopoiesis is largely unexplored. In
humans, mutations of GPR56 have been linked to defects in the
organization of the cerebral cortex in the brain, leading to a
disorder known as bilateral frontoparietal polymicrogyria
(BFPP) (Piao et al., 2004). Due to its abnormal expression
levels in various cancers, GPR56 is also predicted as a tumor
suppressor (Shashidhar et al., 2005). This functional versatility
in various cell types, and the predominant expression pattern
of GPR56 in quiescent HSCs, led us to hypothesize that this
adhesion type receptor might play a critical role in regulating
HSCs.
In this study, we analyzed HSC development and hemato-
poietic function in gene-modified mice deficient for Gpr56.
These studies revealed that a high level of expression of Gpr56
is largely dispensable for the development, maintenance, and
differentiation of adult hematopoietic stem and progenitor
cells (HSPCs) during both steady-state and myeloablative
stress-induced hematopoiesis. These data suggest that low
levels of GPR56 or compensatory functions of related GPCRs
are sufficient to support most hematopoietic functions and
raise questions regarding previously reported defects in the
maintenance and function of adult hematopoietic stem and
progenitor cells in Gpr56-deficient mice (Saito et al., 2013).Materials and methods
Mice
Gpr56-deficient mice (B6N.129S5-Gpr56tm1Lex/Mmcd) were
generated by Genentech (South San Francisco, CA, USA), and
have been reported previously (Li et al., 2008; Koirala et al.,
2009; Wu et al., 2013). Genomic modification of Gpr56
alleles was verified by genotyping PCR using tail tip DNA. The
following primers were used with an annealing temperature
of 58 °C to identify the WT (639 bp) and Gpr56-deficient
(369 bp) alleles: DNA085-5 5′-CGAGAAGACTTCCGCTTCTG-
3′; DNA085-14 5′-AAAGTAGCTAAGATGCTCTCC-3′; Neo3a 5′-
GCAGCGCATCGCCTTCTATC-3′. Wild-type littermates from
heterozygous breeders were used as controls. While prior
studies reported an absence of functional GPR56 protein in
homozygous Gpr56-deficient mice (Saito et al., 2013; Li et
al., 2008; Koirala et al., 2009; Wu et al., 2013), our analysis
by Western blot and flow cytometry suggests residual protein
expression in multiple cellular compartments, including the
brain, liver and hematopoietic system (see Figs. 2B and S2B–
E). B6.SJLPtprca Pep3b/BoyJ (CD45.1) mice were purchased
from The Jackson Laboratory (www.jax.org). All experiments
involving mice were reviewed and approved by the Institu-
tional Animal Care and Use Committee (IACUC) of Joslin
Diabetes Center and Harvard University.
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Digoxigenin-labeled RNA probes were hybridized using the
Ventana Discovery platform (Tucson, AZ). Data can be accessed
at http://www.emouseatlas.org/.Flow cytometry
Total bone marrow (BM), spleen, thymus and peripheral blood
(PB) were harvested from age- and sex-matched mice, as
indicated. BM cells were harvested from long bones (2 tibias
and 2 femurs) by flushing with 25G needle using stainingmedia
(Dulbecco's PBS+ 5% FCS), resuspended, and filtered through a
70 μm cell strainer. BM and splenocytes were subjected
to red blood cell lysis (except when analyzing erythrocytes)
using ACK lysis buffer (Lonza). To identify HSPCs, cells
were stained with biotinylated lineage marker mix (Lin:
anti-CD3e (17-A2), anti-CD4 (L3T4), anti-CD8 (53–6.72),
anti-B220 (RA3-6B2), anti-TER-119, anti-Gr-1 (RB6-8C5),
anti-Mac-1 (M1/70), followed by Streptavidin PE-Texas Red.
Cells were further stained with APC-anti-c-Kit (2B8),
PE-anti-CD150 (TC15-12F12.2), BioLegend), PECy7-anti-Sca-1
(E13-161.7), FITC-anti-CD34 (RAM34), FITC-anti-CD48 (HM48-1)
(eBiosciences); PE-anti-Flt3 (A2F10.1), PE-FcγRII/III (2.4G2)
(BD). BM myeloid progenitor subsets were identified as
follows: common myeloid progenitors (CMP, Lin−Sca1−
cKit+CD34+FcγRII/IIImed), granulocyte monocyte progenitors
(GMPs, Lin−Sca1−cKit+CD34+FcγRII/III+), and megakaryocyte
erythrocyte progenitors (MEPs, Lin−Sca1−cKit+CD34−FcγRII/
IIIlow). Common lymphoid progenitors (CLPs; Lin−CD127+Flt3+)
were identified using Lin mix, PECy7-anti-CD127 (A7R34)
(eBiosciences), and PE-anti-Flt3 (A2F10.1) antibodies. BM
and splenic erythrocyte progenitors, BM megakaryocyte
progenitors, and B-cell progenitor subsets were identified as
previously described (Schepers et al., 2012). For analysis of
immature thymic subsets, Lin mix, APC-anti-c-Kit (2B8),
PECy7-anti-CD25 (M-A251) (BD) were used. Thymocyte differ-
entiation was studied using CD4 and CD8 staining. Mature B
cells, T cells, and myeloid cells were identified using B220+,
CD3+, and CD11b+ Gr1+ staining, respectively. Cell surface
GPR56 expression on BM HSPCs was assessed by using
anti-human GPR56 antibody (clone: CG4, BioLegend).
SYTOX-Blue (Invitrogen) was used to exclude dead cells
during FACS analysis. Stained cells were analyzed on LSRII
flow cytometer, and cell sorting was done on a FACS Aria II
(BD). Data were analyzed by using FACS Diva software
(BD) or FlowJo software (Tree Star). HSPCs from the AGM
were identified by staining with CD41-Brilliant Violet 421
(Biolegend; clone MWReg30), CD34-FITC (BD Bioscience; clone
RAM34), CD45-PE (eBiosciences; clone 30-F11), and cKit-APC
(eBiosciences; clone 2B8). AGM sorts were performed on an
influx cytometer.Peripheral blood (PB) analysis and differential count
PB was collected from the tail vein of adult mice into
EDTA-coated tubes (BD), and differential blood counts
were determined using a Hemavet 950 (Drew Scientific).RT-PCR
For analysis of Col3A and Gpr56 expressions in the AGM,
tissues were dissociated and RNA isolated, reverse tran-
scribed and amplified according to the methods described
in (Fitch et al., 2012), using the following primer sets:
MmGpr56, JP593F 5′-ATCAGCCAGCAGTTACAG-3′ and JP593R
5′-GAAGCAACAGCGAGTATG-3′; MmCol3a, JP596F 5′-GAATCT
GTGAATCATGTCCAACTG-3′ and JP596R 5′-CCACCCATTCCTC
CCACTC-3′; SDHA_F 5′-TTG CTA CTG GGG GCT ACG GGC-3′
and SDHA_R 5′-TGA CCA TGG CTG TGC CGT CC-3′; B-actin_F
5′-TCC TGG CCT CAC TGT CCA-3′ and B-actin_R 5′-GTC CGC
CTA GAA GCA CTT GC-3′. For analysis of Gpr56 expression in
adult cell populations, total RNA was extracted from the
indicated FACS-purified cells by RNeasy micro kit following
manufacturer's instructions (Qiagen) and reverse transcribed
into cDNA using SuperScript Vilo cDNA Synthesis kit
(Invitrogen). Quantitative PCR was performed with an AV7900
PCR system using Taqman Gene Expression master mix kit
(Applied Biosystems). Taqman gene expression primer sets
were used to quantify the Gpr56 (Mm00817704_m1) and
β-actin (Mm00607939_s1) gene expression levels. The expres-
sion levels of the β-actin house-keeping gene were used to
normalize Gpr56 expression in indicated subsets.
Western blot analysis
Total protein lysates from the FACS-sorted BMHSPCs, liver and
embryonic brain (embryonic day (E) 14.5) were subjected to
standard Western blot analysis. Total protein was loaded onto
4–16% gradient SDS-PAGE gel and transferred onto a PVDF
membrane. Mouse anti-human GPR56 monoclonal antibody
(1:500 dilution, Millipore catalog #MABN310 (Jeong et al.,
2012)) was used to detect GPR56 protein. β-Actin (Santa Cruz)
was used as loading control.
Colony-forming unit cell assay (CFU-C)
BM and PB cells were mixed with 300 μL of IMDM and 4 mL of
defined semisolid methylcellulose medium (Methocult GF3434
medium, StemCellTechnologies). Cells were then cultured in
triplicate in 6-well plate with 1.1 mL/plate at a density of
1 × 104 cells for BM and 1 × 105 cells for PB. The total number of
colonies was counted at day 10 under an inverted microscope.
Cell cycle analysis and apoptosis assay
BM and thymocyte cell cycle status was determined using
Ki67/Hoechst staining. Cells were first stained with surface
antibodies to identify indicated subsets and then fixed in
Cytofix buffer for 20 min, washed and permeabilized using
Cytofix/perm buffer (BD) before staining with Ki67-FITC
(B56) antibody (BD) for 30 min at 4 °C. Cells were washed
once with permeabilization buffer after staining and
incubated with Hoechst dye (20 μg/mL) and analyzed by
BD LSR II flow cytometer. To assess the in vivo cell
proliferation rate of thymocytes, 1 mg of BrdU was injected
(i.p.) and mice were sacrificed 5 h later (short-term pulse).
BrdU incorporation was detected with the BrdU flow kit
following the manufacturer's instructions (BD Biosciences).
To assess survival rate, mononuclear cells (1 × 106) from BM
310 T.N. Rao et al.or thymus were surface stained with the appropriate anti-
bodies to identify indicated subsets. Cells were washed with
PBS and then resuspended in 100 μL of Annexin V binding
buffer (BD) and incubated with AnnexinV and 7-AAD (BD
Pharmingen) for 15 min at room temperature. Cells were
resuspended in additional 400 μL of Annexin V binding buffer
and analyzed immediately using a BD LSR II flow cytometer.Bone marrow (BM) reconstitution assays
For competitive repopulation experiments, total BM cells
(1 × 106) from eitherWT control littermates orGpr56-deficient
mice (CD45.2) weremixedwith equal number (1:1) of recipient
type cells (CD45.1) and transplanted into lethally irradiated
(950 rads) B6SJL Ptprca Pep3b/BoyJ (CD45.1) congenic recip-
ients by lateral tail vein injections (in 200 μL PBS/mouse). At
the indicated time points post-transplantation, recipient
mouse PB was collected, erythrocytes were depleted with
ACK buffer (Lonza), and the remaining leukocytes were stained
with anti-mouse CD45.2, CD45.1, CD3, B220, Gr-1, and CD11b
antibodies. Stained cells were analyzed by FACS LSRII (BD).5-FU treatment
5-Fluorouracil (5-FU, Sigma) was administered to mice
intravenously at a dose of 150 mg/kg. Hematopoietic recovery
was monitored by differential blood cell counts using the
Hemavet 950 (Drew Scientific), at indicated time points. For
survival assay, 5-FU was administered intraperitoneally at a
dose of 150 mg/kg weekly for a total of 3 weeks and the
survival of individual mice was monitored daily.In vitro transwell migration assay
In vitro migration of HSPCs was performed using transwells
(6.5 mm diameter inserts; 5 μm pore size; Corning).
FACS-purified HSPCs were loaded onto transwell inserts
(105 cells/well in 100 μL of the medium). The lower
chambers contained 600 μL of RPMI medium supplemented
with 10% FCS and with SDF-1 (100 ng/mL) or without SDF-1
(R&D systems). Cells were incubated for 4 h at 37 °C and 5%
CO2. Migrating cells from the lower chambers were collected
and counted by FACS with normalization using CountBright
Absolute counting beads (Invitrogen). The percentage of
migrated cells was calculated by dividing the absolute number
of migrated cells by the input cell number.In vivo lodging assay
For in vivo lodging assays, FACS-isolated Lin−Kit+ cells from
WT and KO mice were labeled with 4 μM of PKH67 (Sigma)
vital fluorescent dye and intravenously infused into the
non-irradiated wild-type littermates. Sixteen hours post-
transplantation, BM and spleen were harvested from the
recipient mice and analyzed for the labeled lodged cells by
FACS using FITC channel.G-CSF treatment and mobilization assay
Cytokine inducedmobilization of HSPCswas performed by daily
subcutaneous administration of G-CSF (Filgrastim, Amgen),
300 μg/kg in 200 μL of PBS for five consecutive days, as
previously described (Gazit et al., 2013; Neben et al., 1993).
Control mice received PBS only. PB and spleen were collected
on the sixth day and analyzed for HSPC (LSK) frequency by
FACS.
Statistics
Statistical significance was determined with Student's t-test
using GraphPad Prism Software Version 6.0. For the Kaplan–
Meier analysis of survival curves, a log-rank non-parametric
test (Mantel–Cox) was performed. p-Values are denoted with
⁎(p b 0.05); ⁎⁎(p b 0.01); and n.s. (not significant).Results
Gpr56 is abundantly expressed in HSCs during
definitive hematopoiesis in the mouse embryo and
is a heptad target
Recent studies have postulated that genes specifically
expressed in HSCs relative to their more differentiated progeny
may play an important role in fine-tuning HSC properties (Gazit
et al., 2013; Chambers et al., 2007). To identify candidate
HSC-specific regulators we made use of published data sets
that identified genes uniquely expressed by quiescent, versus
proliferating, HSCs (Q-group, (11)) in combination with a
proximal promoter-based analysis of genes that are bound by
seven key hematopoietic transcription factors (Scl, Gata2,
Runx1, Erg, Fli1, Lyl1, and Lmo2) (Wilson et al., 2010), which
together are referred to as Heptad targets (Fig. 1A). Compar-
ative analysis of these gene sets identified a total of 81
transcripts that showed enriched expression in quiescent HSCs
and contained Heptad binding sites in their upstream regions.
Although much attention has been focused on transcrip-
tional regulators of HSCs, it is clear that surface receptors play
an equally important role. Based on the rationale that cell
quiescence is likely to bemediated by niche interactions (Wang
and Wagers, 2011), we further filtered this gene list for cell
surface receptors, identifying eight receptors (Gpr56, Adrb2,
Ifnar2, Vldlr, Fgfr1, Igf1r, Il1r1 and Csf2rb (Il3rBC)) (Supple-
mental Table 1) specifically enriched in quiescent HSCs and
containing Heptad binding sites in their proximal regions. Of
these eight, we focused on Gpr56 for further investigation
because of its unknown physiological function, the availability
of Gpr56-deficient mice, and because prior studies implicated
this receptor in the regulation of adhesion and migration of
neuronal progenitors and malignant cells (Li et al., 2008;
Koirala et al., 2009; Wu et al., 2013). Interestingly, a study
published during the preparation of this manuscript reported a
disruption of HSC localization, cycling and in vivo repopulating
capacity in mice deficient for Gpr56 expression (Saito et al.,
2013).
To determine the role of Gpr56 during the early stages of
hematopoietic development,we examined its expression during
definitive hematopoiesis in the aorta-gonad-mesonephros
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Figure 1 Gpr56 is expressed in HSCs during definitive hematopoiesis in the mouse embryo and is a Heptad target. (A). Venn diagram
showing the overlap between two data sets, one from ChIP-Seq data in HPC7 progenitor cells containing genes with combinatorial
binding regions bound by seven key HSC transcription factors (Scl, Gata2, Runx1, Erg, Fli1, Lyl1 and Lmo2; Heptad targets) (Wilson et
al., 2010) and the other comparing gene expression in quiescent versus proliferating HSCs (Q group) (Venezia et al., 2004). The
overlap (n = 81) between these two data sets was further filtered for cell surface receptors, identifying 8 receptors (Supplemental
Table S1). (B). In situ hybridization for Gpr56 showing transcript expression in blood clusters and adjacent endothelium in E11 AGM
and in E11 FL blood cells. (C). Quantitative PCR for Gpr56 and its ligand Col3a in E11 AGM endothelial cells (EC; CD34+CD45−), E11AGM
mesenchymal cells (MC; CD34−CD45−cKit−), E11 AGM hematopoietic stem cells (HSC; CD34+CD45+cKit+CD41int); E11, E12 FL HSC;
CD34+ckit+ and E14 FL HSC; Lin− CD45+ CD48− CD150+ EPCR+.
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hybridization revealed the expression of Gpr56 transcripts in
emerging clusters of blood cells and adjacent endothelium in
E11 AGM and in E11 FL cells in the mouse embryo (Fig. 1B).
Notably, quantitative RT-PCR analysis revealed that collagen III
(Col3a) the reported ligand of GPR56 (Luo et al., 2011a) is
expressed in E11 AGMmesenchymal cells (MC; CD34−CD45−cKit−
), but not in endothelial cells (EC; CD34+CD45−), or in AGM or FL
HSCs (CD34+CD45+c-kit+CD41int) (Fig. 1C). Conversely, Gpr56
was absent in E11 AGMmesenchymal cells and endothelial cells,
but was significantly elevated in HSCs during the developmental
transition from E11 AGM to E14 fetal liver stages (Fig. 1C),
suggesting a possible role for GPR56 signaling in the regulation
of HSCs during early definitive hematopoiesis. Consistent with
this, a recent study in zebrafish embryos reported a defect in
HSC emergence in the caudal hematopoietic tissue upon gpr56
knockdown by morpholino oligos (Solaimani Kartalaei et al.,
2015).Gpr56 is highly expressed in adult HSCs, but is
dispensable for steady-state maintenance of adult
stem and progenitor cells
We next determined the expression pattern of Gpr56 in
adult bone marrow. Consistent with prior studies (Venezia
et al., 2004), quantitative RT-PCR analysis of purified
HSPCs from adult wild type C57BL/6 bone marrow revealed
that Gpr56 is expressed most abundantly in primitive HSPCs,
with the highest expression detected in long-term,
self-renewing HSCs (LT-HSCs, LSKCD34−Flt3−) followed by
short-term (ST-HSCs, LSKCD34+Flt3−) and multipotent pro-
genitors (MPPs, LSKCD34+Flt3+) (Fig. 2A). Strikingly, Gpr56
expression levels were progressively down-regulated in
lineage-restricted lymphoid and myeloid progenitor subsets
(Fig. 2A). We also analyzed Gpr56 expression across a
broad range of hematopoietic subsets, taking advantage of
two publically accessible databases/web servers, ImmGen
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Figure 2 Gpr56 is highly expressed in adult HSCs, but dispensable for maintaining HSPC numbers in the steady-state. (A). Gpr56
expression was quantified by qRT-PCR analysis in the indicated FACS-purified HSPCs of WT C57BL/6 mice. Expression values in each subset
were normalized to an internal control (β-actin gene). Data are plotted as fold-expression relative to Gpr56 expression in lineage negative
(Lin−) cells, whose expression was arbitrarily set to one. Data represent mean ± SD, n = 4 independent samples from two independent
experiments. (B). Expression of GPR56 on the cell surface of the indicated BM HSPC subsets from WT and Gpr56-deficient mice was
determined by FACS using anti-GPR56 antibody (clone: CG4). (C). Total BM cell numbers of 8–14 week old Gpr56-deficient mice and WT
littermates. Cell counts determined from two tibias and two femurs from each mouse (n = 8 mice per group). (D). Representative FACS
plots showing the percentages of HSPC subsets (as indicated) in the BM of WT and Gpr56-deficient mice. Lin−Sca1+ckit+ (LSK) cells (left
plots) were further fractionated based on CD34 and CD135 expression levels into LT-HSCs (LSKCD34−CD135−), ST-HSCs (LSKCD34+CD135−),
and MPPs (LSKCD34+CD135+) (right plots). (E). Bar graph indicating the frequency of indicated subsets in the whole BM of WT and
Gpr56-deficient mice. Data represent mean ± SEM, n = 10 independent samples from 3 independent experiments. (F). Representative
FACS plots showing the percentages of HSC-SLAM cells (LSKCD48−CD150+), and graph summarizing HSC-SLAM frequency in whole BM of WT
and Gpr56-deficient mice. (G). Detection of myeloid progenitors in the BM by FACS. Lin−Sca-1−c-Kit+ myeloid progenitors (MPs, left FACS
plots) were subdivided according to CD34 and FcγRII/III expression (right FACS plots), the common myeloid progenitors (CMP, Lin−Sca-1−
c-Kit+CD34+FcγRII/IIImed), granulocyte monocyte progenitors (GMPs, Lin−Sca-1−c-Kit+CD34+FcγRII/III+), and megakaryocyte erythrocyte
progenitors (MEPs, Lin−Sca-1−c-Kit+CD34−FcγRII/IIIlow). (H). Frequencies of the indicated subsets in whole BM of WT and Gpr56-deficient
mice. Data represent mean ± SEM, n = 5 independent samples from two independent experiments. (I). FACS plots and graph represent
the frequency of common lymphoid progenitors (CLPs, Lin−CD127+CD135+) in the whole BM of WT and Gpr56-deficient mice. Data are
mean ± SEM, n = 7–10 mice from 3 independent experiments.
312 T.N. Rao et al.(https://www.immgen.org/) and HemaExplorer (http://
servers.binf.ku.dk/hemaexplorer; (Bagger et al., 2012)),
in which microarray based mRNA expression profiles ofpreviously reported FACS sorted populations of immature
and mature hematopoietic subsets can be visualized.
Consistent with our qRT-PCR results, within these data
313High-level Gpr56 expression is dispensable for the maintenance and function of HSPCs in micesets, Gpr56 expression was most abundant in the primitive
HSC fraction, when compared to any other progenitor
subset in the BM or mature hematopoietic cell subset in
the periphery (Supplemental Figs. S1A, B). We also noted
moderate expression of Gpr56 in megakaryocyte progeni-
tors (MkP) in the BM, and in early thymic progenitors
(Supplemental Fig. S1B). Together, these results indicate
that Gpr56 expression is tightly regulated within primitive
HSPCs, and that the level of Gpr56 expression declines
sharply as HSCs undergo lineage restriction and differenti-
ation into mature blood lineages.
These results prompted us to explore further the role of
GPR56 in adult hematopoiesis.We hypothesized that if enriched
expression of Gpr56 predicted its functional activity, then we
could expect to see changes in HSPCs and in steady-state
hematopoiesis inGpr56-deficientmice (Supplemental Fig. S2A).
We thus performed FACS-immunophenotyping to assess the
frequencies of specific HSPC subsets in the BM of adult
Gpr56-deficient mice. Interestingly, although prior studies of
these animals have suggested that they lack GPR56 protein
entirely (Luo et al., 2011a; Saito et al., 2013; Li et al., 2008; Wu
et al., 2013), our analysis using highly specific anti-GPR56 mAb
(Luo et al., 2011a) revealed some residual expression in the
brain, liver, and hematopoietic compartment (Supplemental
Figs. S2B–D). Nonetheless, flow cytometric analysis of HSPC
populations in these animals indicated a substantial reduction
of GPR56 protein on the cell surface, including a N4-fold
reduction of GPR56 staining of LT-HSCs fromGpr56-deficient BM
(Fig. 2B and Supplemental Fig. S2E).
Further analysis of hematopoietic subsets in Gpr56-deficient
mice indicated that, despite the abundant and relatively
restricted expressions of this protein by primitive HSPCs,
Gpr56-deficient mice displayed no abnormalities in steady-
state hematopoiesis. Total BM cellularity and frequencies of
LT-HSC (LSKCD34−CD135−), ST-HSC (LSKCD34+CD135−) and
MPPs (LSKCD34+CD135+) in the BM were indistinguishable
from WT control littermates (Figs. 2C–E). Likewise, further
enrichment of HSCs within the LSK subset, using SLAM family
receptor expression (LKSCD150+CD48− (Kiel et al., 2005)), also
revealed HSC frequencies that were unaffected by the
reduction of Gpr56 (Fig. 2F). We did observe a mild reduction
in LT-HSC (LSKCD34−CD135−) frequency in Gpr56-deficient
BM, but this reduction was not statistically significant
(p = 0.209). A detailed analysis of lineage committedTable 1 Differential blood cell counts on peripheral blood from
Parameter Gpr56+/+
WBCs (K/μL) 9.29 ± 5.12
Neutrophils (K/μL) 2.71 ± 1.91
Lymphocytes (K/μL) 5.74 ± 4.09
Monocytes (K/μL) 0.51 ± 0.3
Eosinophils (K/μL) 0.26 ± 0.19
Basophils (K/μL) 0.04 ± 0.07
RBC (M/μL) 9.42 ± 1.25
Hb (g/dL) 12.84 ± 1.89
HCT (%) 46.65 ± 6.21
MCV (fL) 49.46 ± 2.89
PLT (K/μL) 766.58 ± 200.12
Values shown are means ± SEM (n = 12 mice per group). WBC indicates
hematocrit; MCV, mean corpuscular volume; and PLT, platelets. No stprogenitors, including myeloid progenitors (MPs), common
myeloid progenitors (CMPs), granulocyte monocyte progen-
itors (GMPs), and megakaryocyte erythrocyte progenitors
(MEPs), and common lymphoid progenitors (CLPs) similarly
showed frequencies indistinguishable from those in wild
type BM (Figs. 2G–I and Supplemental Figs. S3A–B). B-cell
progenitors were mildly decreased at the Pre-B and Pro-B
stages; however, this defect was resolved at the mature B
cell stage (Supplemental Figs. S3C–D).
We also performed detailed immunophenotyping and
differential blood counts of mature hematopoietic lineages
in the BM and PB to determine if specific lineages might be
affected in Gpr56-deficient mice. The frequencies of mature
T-cells (CD3+), B-cells (B220+), myeloid cells (CD11b+Gr-1+),
and erythroid lineage cells in the BM and the overall PB cell
counts were unchanged, indicating unaffected lymphopoiesis
and myelopoiesis in mice with reduced levels of functional
GPR56 (Table 1 and Supplemental Figs. S3C, E–G). Altogether,
these results indicate that despite its enriched expression
in primitive HSPCs, high level GPR56 is largely dispensable
for steady-state HSPC maintenance and hematopoietic
differentiation.Enlarged thymuses and increased frequency of early
thymic precursors in Gpr56-deficient mice
To further assess any effects on blood cell development in
the absence of high levels of GPR56, we investigated
hematopoiesis in the spleen and thymus of Gpr56-deficient
mice. Analysis of splenic lineages revealed normal cellularity
and frequencies of myeloid, B-cells and erythroid lineages
(Supplemental Figs. S4A–C); however, the frequencies of
CD4+ and CD8+ T cells were slightly but significantly reduced
in Gpr56-deficient mice (Figs. S4D–E). We also consistently
observed enlarged thymuses in Gpr56-deficient mice com-
pared with age-matched littermate controls (Fig. 3A).
Thymic analysis showed that Gpr56-deficient mice at
8–14 weeks of age exhibited significantly higher numbers
of thymocytes (~1.4-fold) compared with age-matched
controls (159 ± 7 for WT and 225 ± 13 for Gpr56-deficient
mice, p = 0.0002) (Fig. 3B). In addition, histological analysis
revealed that the thymus of Gpr56-deficient mice possessedGpr56+/+ and Gpr56def littermates.
Gpr56def p-Value
6.87 ± 3.78 0.20
1.56 ± 0.75 0.10
5.03 ± 3.04 0.64
0.24 ± 0.29 0.13
0.03 ± 0.03 0.06
0.01 ± 0.01 0.12
9.03 ± 2.21 0.58
12.33 ± 3.21 0.64
45.57 ± 12.05 0.78
50.13 ± 2.58 0.58
829.42 ± 206.48 0.43
white blood cell; RBC, red blood cell; Hb, hemoglobin; HCT
atistically significant differences were detected.
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Figure 3 Enlarged thymus and increased frequency of early thymic precursors in Gpr56-deficient mice. (A). Representative
photographs of thymuses from 10-week-old WT and Gpr56-deficient mice. (B). Increased thymic cellularity in Gpr56-deficient mice.
Graph shows the absolute number of thymocytes from the indicated age group of WT or Gpr56-deficient mice (mean ± SEM, n = 9–12
mice). (C). Hematoxylin and eosin (H&E) staining of thymus from 12-week old WT and Gpr56-deficient mice (representative of n = 4
per genotype) (m: medulla; c: cortex). (D). FACS contour plots display the distribution and percentages of immature thymocyte
subsets within the Lin− fraction of thymocytes from 10-week-old WT and Gpr56-deficient mice. (E–F). Graphs show the frequencies
(E) and absolute number of thymocytes (F) of indicated immature thymocyte subsets in the thymus (n = 12 mice per genotype,
mean ± SEM). (G). Thymocytes from 10-week-old WT and Gpr56-deficient mice were surface stained for CD4 and CD8 to assess
thymocyte differentiation. FACS plots show the distribution of DN (CD4−/CD8−), DP (CD4+/CD8+), CD4+ and CD8+ cells. Graphs show
the percentages of indicated subsets in the thymus (n = 11 mice). (H). Mice were treated by i.p. injection of 1 mg of BrdU and
sacrificed 5 h later. The data show percentage of cells with BrdU-incorporation in the indicated thymic subsets (n = 5, means ± SEM).
(I). Apoptosis rates in the thymocytes from 8-week-old WT and Gpr56-deficient mice were determined by Annexin V/7-AAD staining.
Percentages of apoptotic cells are summarized in the graph (n = 5, means ± SEM). *p b 0.05, **p b 0.01, and n.s. (not significant).
314 T.N. Rao et al.abnormal cortex and medullary proportions with an enlarged
medullary region (Fig. 3C).
It has been reported that increased frequency of early
thymic progenitors (ETP) due to increased recruitment of
progenitors from the BM into the thymus could led to increased
thymic cellularity (Schnell et al., 2006). Therefore, we
next studied the early stages of thymocyte development todetermine whether Gpr56-deficiency increased the ETP and
CD4/CD8-double negative thymocyte subsets. Fractionation
of Lin− thymocytes using CD25 and c-Kit surface expression
revealed that Gpr56-deficient mice have significantly higher
percentages and absolute numbers of ETPs (Lin−CD25−c-Kit+)
in the thymus (Figs. 3D–F). Analysis of subsequent develop-
mental stages showed that Gpr56-deficient mice also
315High-level Gpr56 expression is dispensable for the maintenance and function of HSPCs in micepossessed higher numbers of DN2 (Lin−CD25+c-Kit+), DN3 (Lin−
CD25+c-Kitlo) and mature CD4 and CD8 single positive cell
subsets (Figs. 3D–G, and data not shown).
It is possible that increased cycling or survival of early
thymic precursors could account for the increased cellularity
in Gpr56-deficient mice. Thus, to determine cellular prolifer-
ation rates, we pulsed these mice with BrdU for 5 h and
analyzed the frequency of BrdU+ cells; however, WT and
Gpr56-deficient ETPs and DN2 cells showed comparable
proliferation rates (Fig. 3H). Cell survival measurements
using Annexin V staining likewise showed that Gpr56-deficient
ETPs exhibited similar rates of apoptosis as their WT counter
parts (Fig. 3I). Analysis of all other developmental stages,
including CD4+, CD8+, and DP stages, also showed comparable
rates of cycling and comparable frequencies of apoptotic cells
between WT and Gpr56-deficient thymocytes (data not
shown). The observed increase in the number of ETPs and
DN2 cells in Gpr56-deficient thymuses, despite normal
proliferation and survival rates, suggests that Gpr56 deficien-
cy may alter the intrinsic ability of Gpr56-deficient BM
progenitors to migrate from the BM into the thymus. It is also
possible that Gpr56-deficient thymuses may be more recep-
tive to BM progenitor entry. Regardless, increased numbers of
ETPs and DN2 cells likely account for the increased number of
subsequent thymocyte stages, and hence the overall increase
in thymic cellularity.High-level GPR56 expression is largely dispensable
for regulation of HSPC proliferation and survival and
for reconstitution of the hematopoietic system after
BM transplantation
Although detailed immunophenotyping analysis by flow cytom-
etry suggested no reduction in HSPC content inGpr56-deficient
BM (Fig. 2), it is possible that homeostatic effects during
development could mask defects in HSPC maintenance in
Gpr56-deficient mice through functional compensatory mech-
anisms. Therefore, we next tested whether changes in cell
proliferation or survival might have provided a selection
advantage toward normal HSPC pool size. To directly assess
the cell-cycle status of Gpr56-deficient HSPCs, we stained the
cells with Ki-67, a proliferation marker, and Hoechst 33342 for
DNA content analysis. No differences were noted in the
percentages of quiescent (G0, Ki67−Hoechst−) or cycling cells
(S/G2/M, Ki67+Hoechst+) in WT and Gpr56-deficient HSPC
subsets (Figs. 4A–B). Next, we co-stained cells with Annexin V
and 7-AAD and analyzed possible effects on survival by flow
cytometry. The percentages of early apoptotic cells (Annexin
V+ 7-AAD−) among Gpr56-deficient LSK HSPCs cells were not
significantly different from WT littermates (Fig. 4C, 6.88 ±
1.13 and 5.83 ± 0.8, for Gpr56-deficient and WT, respectively)
(p = 0.47). These findings are in line with our earlier
observations that phenotypic HSPCs are largely intact in
Gpr56-deficient BM. Altogether, these results suggest that
Gpr56-deficiency does not affect HSPC quiescence or
survival in the adult mouse bone marrow during steady-state
conditions.
To evaluate the hematopoietic reconstituting ability
of Gpr56-deficient HSCs, we next performed competitive
repopulation assays in which equal numbers of total BM cells
(CD45.2+) from WT or Gpr56-deficient mice were mixed at a1:1 ratio with congenic (CD45.1+) WT competitor cells and
transplanted into lethally irradiated primary recipient mice
(Fig. 4D). Previously, Saito et al. (2013), reported that
Gpr56-deficient HSCs possess reduced reconstitution potential
due in part to reduced homing capacity. We speculated that if
GPR56 regulates HSC homing capacity we should see an
alteration in hematopoietic repopulation in recipients partic-
ularly at early stages after BM transplantation; however,
analysis of peripheral blood of recipient mice at 4-weeks after
transplant showed no significant differences between WT and
Gpr56-deficient donors in either the reconstitution of total
hematopoietic lineages (percent CD45.2+) or the repopulation
of B (B220+), T (CD3+) and myeloid cells (Gr1+CD11b+)
(Figs. 4E–H), suggesting that high level GPR56 expression
is not needed for HSC homing or short-term reconstitution
in primary transplant recipients. Subsequent analysis of
long-term reconstitution, at 8, 12, and 20 w post-BMT,
revealed that Gpr56-deficient donors did not differ in their
ability to reconstitute B, T, and short-lived myeloid cells (a
measure for intact HSC activity) in the PB or BM of primary
recipients (Figs. 4E–I). Furthermore, the frequencies of donor
LSK cells in the BM of primary recipient mice were also similar
(80.9 ± 5.9 vs. 70.8 ± 22.5, p = 0.41) in the two groups (Fig. 4J).
To further assess the regenerative capacity of Gpr56-
deficient HSCs, we performed secondary transplantation
(which imposes extreme proliferative stress for HSCs) using
total BM cells from primary recipients harvested 20 weeks
after the primary transplant. Intriguingly, while donor
B-cell and T-cell chimerism was almost identical in
secondary recipients of WT and Gpr56-deficient marrow,
donor myeloid lineage chimerism in the PB (p = 0.001) and the
total donor cell frequency in the BM was significantly reduced
(p = 0.0027) in secondary recipients of Gpr56-deficient BM
(Figs. 4K–L). Analysis of the LSK compartment also showed a
significant reduction of HSPC frequency (86.3 ± 11.7 for WT vs
42.2 ± 24.6 for Gpr56-deficient mice, p = 0.006) in secondary
recipients of Gpr56-deficient BM (Fig. 4M). Taken together,
these results indicate that although high levels of GPR56
appear dispensable for hematopoietic reconstitution in pri-
mary recipients, Gpr56-deficient HSCs can show reduced
regenerative capacity when subjected to repeated prolifera-
tive stress induced by serial BM transplantation.Gpr56-deficiency does not alter recovery from
myelosuppression or impair the physiological or
pharmacological mobilization of HSPCs
The defects we observed upon serial transplant of Gpr56-
deficient BM cells suggested that reduction of GPR56 protein
levels on HSPCs might impact the hematopoietic function of
these cells when subjected to repeated proliferative or
migratory stress. During steady-state conditions, the majority
of HSCs are maintained in a quiescent state (G0) in the BM;
however, during infections, and in response to irradiation or
chemotoxic drugs, HSCs exit quiescence and enter the cell
cycle to replenish the hematopoietic system. These cells also
can be induced by such stimuli tomigrate from the BM niche to
seed extramedullary hematopoiesis (Wright et al., 2002).
During these responses, the balance between proliferation
and differentiation must be tightly controlled to sustain the
316 T.N. Rao et al.ability of HSCs to regenerate the hematopoietic system
(Passegue et al., 2005).
To elucidate whether GPR56 plays any role regenerating
the hematopoietic system during such conditions, we treated
mice with a single dose of 5-fluorouracil (5-FU) intravenously,
a cytotoxic drug that kills actively cycling cells and induces
quiescent HSCs to rapidly proliferate. We monitored theGpr56+/+
Gpr56def
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Gpr56+/+ Gpr56dkinetics of hematopoietic recovery in the peripheral blood at
every fourth day for a total of 24 days after 5-FU treatment. In
agreement with previous studies, we observed multi-lineage
hematopoietic recovery, including white blood cells (WBC),
platelets, and red blood cells (RBC), at days 16–20 after 5-FU
treatment in the peripheral blood of WT mice (Figs. 5A–C).
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Figure 5 Normal hematopoietic recovery and survival of Gpr56-deficient mice after myelosuppressive treatment with 5-FU. Eight
to ten week-old WT and Gpr56-deficient mice were intravenously injected with a single dose of 5-FU (150 mg/kg), and the kinetics
of hematopoietic recovery was measured in the peripheral blood at the indicated time. Recovery of white blood cells (WBC)
(A), platelets (B), and red blood cells (RBC) (C). Data are from 2 independent experiments (n = 8–10 mice, plotted as mean ± SD).
(D). Gpr56-deficient mice exhibit normal sensitivity to repetitive myelosuppressive stress. Mice were injected intraperitoneally with
5-FU weekly for a total of 3 weeks, and survival was monitored daily. Survival data were analyzed using a log-rank non-parametric
test (Mantel–Cox test), and shown as Kaplan–Meier survival curves (n = 12 animals per genotype over two independent experiments).
317High-level Gpr56 expression is dispensable for the maintenance and function of HSPCs in micerecovery kinetics and cell numbers between Gpr56-deficient
mice and WT littermates. We next sought to determine the
involvement of GPR56 signaling in HSC cell cycle regulation
during myeloablative stress, as it has been reported that
repetitive 5-FU treatment brings HSCs into continuousFigure 4 Gpr56 deficiency does not impair HSC engraftment and m
plots show the distribution of cell cycle stages of BM HSPC subsets from
define the HSPC subsets and further stained intracellularly for Ki-67 and
cycle: G0 (Ki-67lo Hoechst−), G1 (Ki-67+ Hoechst−), and S/G2/M (Ki-67+
mean ± SEM). (C). Apoptosis rates among BM LSK cells from WT or G
Representative FACS plots show the percentages of apoptotic cells am
apoptotic cells (Annexin V+ 7-AAD−) among LSK cells (n = 8 mice pe
transplantation assay: Total BM cells from CD45.2+ WT or Gpr56-defic
recipient-type BM cells (1:1) and competitively transplanted into lethall
BM from primary recipients was transplanted into secondary recipients
(CD45.2+) in primary recipient mice was determined by FACS analysis o
cells (CD45.2+) (E); donor B-cells (CD45.2+B220+) (F); donor myeloid cell
the indicated time points (n = 7–8 mice, mean ± SD). (I–J). At 20-w
donor-derived cells (CD45.2+) (I) and donor LSK frequency (J). (n = 7
recipients. Donor chimerism in peripheral blood at 4 and 12 weeks
donor-derived LSK cells in the BM at 12 weeks after secondary transplan
(not significant).proliferation and ultimately leads to their exhaustion
(Schepers et al., 2012). We treated mice with 5-FU (150 mg/
kg, i.p.) once per week for a total of 3 weeks, and monitored
the survival ofmice daily; however, themedian survival rates of
Gpr56-deficient mice were not significantly different from WTulti-lineage repopulating activity in vivo. (A). Representative FACS
WT or Gpr56-deficient mice. BM cells were first surface stained to
Hoechst 33342. (B). The percentages of cells in each stage of cell
Hoechst+), are summarized in the graph. (n = 5 mice per genotype,
pr56-deficient mice as determined by Annexin V/7-AAD staining.
ong LSK cells. The bar graph represents the percentages of early
r genotype, mean ± SEM). (D). Schematic of serial competitive
ient mice were mixed with equal numbers of congenic (CD45.1+)
y irradiated primary (CD45.1+) recipient mice. After 20 weeks, total
at 1 × 106 cells per secondary recipient. (E–H). Donor chimerism
f peripheral blood. Bar graphs show the percentages of total donor
s (CD45.2+CD11b+Gr1+) (G); and donor-T cells (CD45.1+ CD3+) (H) at
eeks after transplantation, recipient BM was analyzed for total
mice, mean ± SD). (K–M). Analysis of secondary BM transplant
post-transplant (K). Total donor chimerism in BM (L). Percent
tation (n = 6 mice, mean ± SD) (M). *p b 0.05, **p b 0.01, and n.s.
318 T.N. Rao et al.littermate controls (13 days vs. 16 days for Gpr56-deficient
mice and WT mice, respectively; p = 0.106). (Fig. 5D). These
data indicate that Gpr56-deficiency does not significantly
affect hematopoietic regeneration during hematopoietic re-
covery from myeloablative stress.
Bone marrow HSPC retention and release are fine-tuned by
the orchestrated action of molecular signals generated by
cell-intrinsic and extrinsic cues within the BM microenviron-
ment (Dar et al., 2006; Greenbaum and Link, 2011). GPR56 hasE
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Gbeen implicated in the regulation of migration and adhesion
of neuronal progenitor cells and various malignant cells via
Gα12/13 and Rho GTPase signaling pathways (Iguchi et al.,
2008; Shashidhar et al., 2005; Koirala et al., 2009). We
therefore examined whether GPR56 might also be involved in
the regulation of HSPC migration. To this end, we performed
in vitro transwell migration assays to assess the ability of
Gpr56-deficient HSPCs to migrate in response to a gradient of
SDF-1α (Fig. 6A), a ligand for CXCR4 and a well-describedgreen)
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2006). Both WT and Gpr56-deficient HSPCs migrated well in
response to SDF-1α, suggesting that Gpr56-deficiency on
HSPCs does not impair their migratory capacity.
To directly assess the ability of HSPCs to interact with their
niche in vivo, we next performed an in vivo lodgment assay in
which an equal number of FACS-purified Lin−Kit+ cells
(enriched for HSPCs) from WT or Gpr56-deficient mice BM
were fluorescently labeled and transplanted intravenously
into non-irradiated WT littermates (Luo et al., 2011b).
Sixteen-hours post-transplantation, we assessed the frequen-
cy of cells within the BM and spleen (Figs. 6B–D). Labeled cells
from Gpr56-deficient mice were lodged in the BM (p = 0.74)
and spleen (p = 0.17) of recipient animals with similar
frequency to their WT counterparts. We also analyzed HSPC
frequencies in the peripheral blood (PB) and spleen in the
steady-state using colony-forming assays and FACS. Both WT
andGpr56-deficientmice displayed similar HSPC content in PB
and spleen (Figs. 6E–I), suggesting that GPR56 does not
regulate bone marrow HSPC retention or trafficking under
physiological conditions. Finally, to test the effect of Gpr56-
deficiency on pharmacologically-induced HSPC mobilization,
we treated mice with G-CSF for five days, a commonly used
regimen in clinical settings to induce HSPC mobilization for
transplantation therapies (Neben et al., 1993; Wright et al.,
2002). Again, we saw no differences in circulating HSPC
frequencies between G-CSF-treated WT and Gpr56-deficient
mice (Figs. 6E–I). Collectively, these results suggest that
reduction of Gpr56 does not affect BM HSPC retention or
release in the steady-state or in response to G-CSF-induced
mobilization.Discussion
In this study, we explored the expression pattern and
functional significance of GPR56 in the regulation of
hematopoietic stem and progenitor maintenance and func-
tion during steady-state and stress-induced hematopoiesis.
We found that Gpr56 is predominantly expressed in primitive
HSPCs during embryonic definitive and adult hematopoiesis
and is regulated in adult BM by core HSC transcription
factors. Yet, despite its predominant expression in HSCs,
high level Gpr56 expression appears largely dispensable for
HSC maintenance in the bone marrow of mice. While we
were undertaking this study, Saito et al. (2013), reported
that GPR56 signaling maintains HSC quiescence and reten-
tion in BM niches via regulation of apoptosis, cell cycle,Figure 6 Gpr56 deficiency does not affect the physiological or phar
of FACS isolated LSK cells from WT or Gpr56-deficient mice was asse
cells after 4 h was determined for spontaneous migration (no SDF-1
SDF-1α gradient). Cell migration was quantified by FACS analysis (n
in vivo lodging assay. (C). Representative FACS plots showing the per
and spleen of recipient mice. (D). Bar graph summarizes the frequ
animals per group, mean ± SD. (E). Total number of colonies formed
per genotype) in methylcellulose based colony-forming unit (CFU) ac
percentages of LSK and myeloid progenitor cells (LS−K+) among the Lin
or G-CSF-treated (bottom) WT or Gpr56-deficient animals. Graphs sh
spleen (I) from untreated and G-CSF treated WT and Gpr56-deficien
experiments (n = 7–8 animals per group).adhesion, and migration through Rho-GTPase signaling, and
in a Evi1-regulated manner (Saito et al., 2013). However, in
our studies, we were unable to identify any differences in
HSPC maintenance or differentiation capacity associated
with the reduction of GPR56. Although the Gpr56−/− mice
studied by Saito et al. (2013), and the Gpr56-deficient mice
used in this study were generated by and obtained from the
same source as that used in other studies of GPR56 function
(Saito et al., 2013; Li et al., 2008; Koirala et al., 2009; Wu et
al., 2013), all of the hematopoietic subsets we investigated,
including phenotypic HSPCs and mature cell lineages in
bone marrow, spleen, and blood were intact in the Gpr56-
deficient mice, at least under the conditions tested here.
There were, however, subtle phenotypes observed in our
Gpr56-deficient mice, including an enlarged thymus, in-
creased frequency of early thymic precursors and CD4+ T
cells, and lower percentages of CD4+ and CD8+ T cells among
lymphocytes in the spleen suggesting a possible role for
GPR56 in the regulation of mature T lymphopoiesis in the
thymus. Increased ETP and DN2 frequency despite normal
proliferation and survival suggests that in the steady state
GPR56 signaling may negatively regulate the entry of
progenitors into the thymus. Similar observations were
reported for mice deficient for the transcription factor
Egr1 (Schnell et al., 2006), although further studies will be
required to unravel the cellular and molecular mechanisms
through which GPR56 regulates thymus size.
Gpr56-deficient HSPCs displayed proliferation and
apoptotic rates similar to that of WT HSPCs in vivo. Moreover,
in contrast to previous studies (Saito et al., 2013), Gpr56-
deficient HSPCs were able to regenerate the hematopoietic
system normally in irradiated recipient mice in primary
competitive BM transplantation settings. Gpr56-deficient
HSPCs also displayed a normal pattern of hematopoietic
recovery from myelosuppression after treatment with 5-FU
in vivo, indicating that high levels of Gpr56 expression are not
required for the repopulating activity of HSCs in vivo, although
themild impairment of reconstituting activity seen upon serial
transplant of Gpr56-deficient HSPCs suggests that sustained
GPR56 activity may be important for maintaining hematopoi-
etic function during prolonged hematopoietic stress. Our
observations that HSPC numbers and functions remain intact
in Gpr56-deficient mice despite disruption of both Gpr56
alleles and substantial reduction of GPR56 protein is consis-
tent with a recent report focused on stem cell function in
skeletal muscle, which likewise found no significant muscle
phenotypes in Gpr56-deficient animals or patients (Wu et al.,
2013).macologically-induced migration of HSPCs. (A). In vitro migration
ssed in Transwell migration assays. The percentage of migrated
α) or in response to chemotactic signals (toward 100 ng/ml of
= 4 mice per experimental group, mean ± SD). (B). Schematic of
centages of labeled lodged cells (PKH67+ cells, green) in the BM
ency of lodged cells among the live BM and spleen cells (n = 4
from PB cells (1 × 105) from WT or Gpr56-deficient mice (n = 4–5
tivity assay (mean ± SD. (F and H). FACS contour plots show the
− cells of peripheral blood (F), and spleen (H) from untreated (top)
ow the frequencies of LSK cells in the peripheral blood (G), and
t mice. Data are plotted as mean ± SD, from two independent
320 T.N. Rao et al.G-protein coupled receptors are highly conserved across
species and show structural homology with the other
members of this family, and their mechanisms of action
can be context-dependent and tissue specific
(Venkatakrishnan et al., 2013; Wu et al., 2013;
Kinzer-Ursem and Linderman, 2007). GPR56 signaling has
been implicated in the regulation of neuronal progenitor
cell adhesion and migration in the brain; however, we failed
to detect such functions for GPR56 in HSPCs in the BM
microenvironment, illuminating the tissue-specific, and
context-dependent regulation of GPR56 signaling. The
underlying basis for the distinct functions of GPR56 in the
brain versus other tissue remains unclear. It is possible that
closely related GPCR proteins or other unknown factors can
compensate for reduced GPR56 in the adult hematopoietic,
but not neural, progenitors. Potentially confounding com-
pensatory signals arising from hematopoietic and
non-hematopoietic cells (such as, HSPC niche components)
in response to germline disruption of Gpr56 and could also
provide a selection advantage during homeostasis toward
maintaining normal HSPC numbers in vivo. Finally, given
our surprising observation that residual GPR56 protein can
be detected using a mouse anti-human GPR56 monoclonal
antibody in Gpr56-deficient mice, which previously have
been reported to lack this protein entirely based on staining
with a rabbit anti-human GPR56 antibody that was
pre-cleared with mouse brain homogenates from GPR56
knockout mice, we cannot exclude the possibility that the
residual protein expression we detect in these mice (Fig. 2B
and Supplemental Figs. S2B–E) is sufficient to mediate the
crucial functions of GPR56 in HSPCs, though perhaps not in
other cell types. Furthermore, humans and mice harbor four
splicing variants of GPR56, among which the S4 variant has its
starting ATG in exon 4 of the gene (Kim et al., 2009). The
targeting strategy used to generate the Gpr56-deficient mice
used in this and prior studies (Luo et al., 2011a; Saito et al.,
2013; Koirala et al., 2009; Wu et al., 2013) was designed to
delete exons 2 and 3, and likely fails to delete the S4 variant.
Thus, it is possible that the existing Gpr56 knockout allele is
actually a hypomorphic allele and that the generation of new
targeting constructs that delete all forms of GPR56 will reveal a
role for this protein in physiological processes that can proceed
relatively normally with even very low levels of receptor. It is
also possible that different levels of residual protein expression
or different ratios of GPR56 splice variants in Gpr56−/− mice
housed in different animal facilities might ultimately provide
an explanation for the different hematopoietic phenotypes
observed in Gpr56-deficient mice in our studies and those of
Saito et al. (2013), as a slightly higher level of residual GPR56
protein in our animals might be sufficient for GPR56 to
perform its normal physiological functions. Such impacts of
housing conditions on animal phenotype have been noted
in other studies, which have further implicated differences
in microbiome composition as a critical underlying variable
(Kriegel et al., 2011). Further studies to identify GPR56
regulatory or compensatory signals and/or conditional deletion
of Gpr56 in specific hematopoietic lineages will be very helpful
for further dissecting the activities of Gpr56 in physiological and
regenerative hematopoiesis. In any event, our data clearly
argue that high level Gpr56 expression is largely dispensable for
adult hematopoietic stem and progenitor cell maintenance in
the BM niche and regenerative functions in mice.Summary
This work identifies the G-protein coupled receptor GPR56
as a cell surface protein that is expressed predominantly in
long-term reconstituting hematopoietic stem and progenitor
cells (HSPCs) in the adult bone marrow and regulated by a
core set of hematopoietic transcription factors. However,
despite enriched expression in HSPCs, reduced expression of
GPR56 in gene-targeted Gpr56-deficient mice, revealed only
subtle alterations in the hematopoietic compartment, with
normal HSPC functions in both steady-state and regenerative
hematopoiesis. Gpr56-deficiency also did not disrupt the
physiological or pharmacologically-induced migration of
HSPCs. These data suggest that high-level expression of
GPR56 is dispensable for adult blood cell formation.Acknowledgments
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